IP Library Granted Patent US 10,851,173
Granted Patent B2
US 10,851,173 · App. 16/219,528 · Granted Dec 1, 2020

Anti-OX40 antibodies and methods of using the same

Inventors: Yong-Jun Liu (Pearland, TX); Kui Shin Voo (Pearland, TX); Laura Bover (Pearland, TX); Naoya Tsurushita (Palo Alto, CA); J. Yun Tso (Menlo Park, CA); Shankar Kumar (Pleasanton, CA)
Assignee: Board of Regents, The University of Texas System
C07K16/2878A61K2039/505C07K2317/24C07K2317/56C07K2317/565C07K2317/74C07K2317/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,851,173
App. No.
16/219,528
Granted
Dec 1, 2020
Kind
B2
Abstract

Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

Claims (12)

1. An isolated nucleic acid encoding an antibody or antigen binding portion thereof which binds to OX40 comprising: (a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 7; (e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 8; and (f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 9; or an isolated nucleic acid encoding an antibody or antigen binding portion thereof which binds to OX40 comprising: (a′) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 13; (b′) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 14; (c′) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 15; (d′) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 19; (e′) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 20; and (f′) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 21.

2. An isolated nucleic acid encoding an antibody or antigen binding portion thereof that binds OX40 comprising (a) the amino acid sequence of SEQ ID NO: 7 or 19, or an antibody or antigen binding portion thereof comprising an amino acid sequence with 90 percent homology to the amino acid sequence of SEQ ID NO: 7 or 19; (b) the amino acid sequence of SEQ ID NO: 8 or 20, or an antibody or antigen binding portion thereof comprising an amino acid sequence with 90 percent homology to the amino acid sequence of SEQ ID NO: 8 or 20; (c) the amino acid sequence of SEQ ID NO: 9 or 21, or an antibody or antigen binding portion thereof comprising an amino acid sequence with 90 percent homology to the amino acid sequence of SEQ ID NO: 9 or 21; (d) the amino acid sequence of SEQ ID NO: 1 or 13, or an isolated nucleic acid encoding an antibody or antigen binding portion thereof comprising an amino acid sequence with 90 percent homology to the amino acid sequence of SEQ ID NO: 1 or 13; (e) the amino acid sequence of SEQ ID NO: 2 or 14, or an antibody or antigen binding portion thereof comprising an amino acid sequence with 90 percent homology to the amino acid sequence of SEQ ID NO: 2 or 14; (f) the amino acid sequence of SEQ ID NO: 3 or 15, or an antibody or antigen binding portion thereof comprising an amino acid sequence with 90 percent homology to the amino acid sequence of SEQ ID NO: 3 or 15.

3. An isolated nucleic acid encoding an antibody or antigen binding portion thereof that binds to an epitope on OX40 recognized by an antibody (a) having a heavy chain variable region comprising the amino acid sequences of SEQ ID NO: 5 or 17 and a light chain variable region comprising the amino acid sequences of SEQ ID NO: 11 or 23, or an antibody or antigen binding portion thereof having amino acid sequences with at least 90 percent homology thereto; or (b) having a light chain variable region having CDRs comprising the amino acid sequences of SEQ ID NO: 7 or 19, SEQ ID NO: 8 or 20, SEQ ID NO: 9 or 21, or an antibody or antigen binding portion thereof having amino acid sequences with at least 90 percent homology thereto; or (c) having a heavy chain variable region having CDRs comprising the amino acid sequences of SEQ ID NO: 1 or 13, SEQ ID NO: 2 or 14, SEQ ID NO: 3 or 15, or an antibody or antigen binding portion thereof having amino acid sequences with at least 90 percent homology thereto.

4. The nucleic acid of claim 1 , comprising a heavy chain variable region of SEQ ID NO: 5 and a light chain variable region or SEQ ID NO: 11.

5. The nucleic acid of claim 1 , comprising a heavy chain variable region of SEQ ID NO: 17 and a light chain variable region of SEQ ID NO: 23.

6. An isolated vector comprising the nucleic acid of claim 1 .

7. A host cell comprising a vector comprising the nucleic acid of claim 1 .

8. The host cell of claim 7 , wherein said host cell is a eukaryotic cell.

9. The host cell of claim 7 , wherein said host cell is a mammalian cell.

10. The host cell of claim 7 , wherein said vector is an expression vector.

11. A method of producing an antibody or antigen binding portion thereof comprising the step of culturing the host cell of claim 10 .

12. The method of claim 11 , further comprising recovering the antibody or antigen bindng portion thereof from the host cell.